Precision Biosciences Inc (DTIL) - News Archive

Gene Editing Advances: Precision BioSciences Unveils Promising HBV Trial Results and Strategic Insights In an era marked by dynamic scientific advancements, Precision BioSciences, Inc., a frontrunner in the realm of gen...

Precision BioSciences: Navigating Losses Amid Promising Developments in Gene Editing Precision BioSciences, Inc. is set to announce its first quarter 2025 financial results on May 15. As the company navigates the comple...

Precision BioSciences to Engage in Investor Conferences Amidst Market Challenges Precision BioSciences, a prominent player in the field of genome editing and therapeutic development, is set to participate in a series of...

DURHAM, N.C. Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing enterprise, has revealed compelling preclinical data today that supports the advancement of its innovative therapeutic candidate, PB...

Precision BioSciences: Navigating Challenges and Achievements in the Gene Editing Landscape Precision BioSciences, Inc. a clinical-stage gene editing company based in Durham, North Carolina, continues to make strides in...

Revolutionizing Gene Editing: Precision BioSciences Strategic Advances in Viral Hepatitis and Oncology Precision BioSciences Inc. a key player in the advanced gene editing sphere, is gearing up for significant milestone...

In the rapidly evolving landscape of modern medicine, the pursuit of innovative therapies for chronic viral infections has reached a critical juncture. Precision BioSciences, Inc. (NASDAQ: DTIL), a pioneer in the field...

In recent weeks, Precision BioSciences, Inc. (Nasdaq: DTIL) has made significant strides in the field of gene editing, showcasing its commitment to innovative therapies that hold the promise of transforming the treatmen...

Precision BioSciences Inc. recently garnered attention as it received $13 million from the maturity of a convertible note with Imugene, a transaction that forms part of the August 2023 Azer-cel deal. While this financia...

Precision BioSciences Clears Milestone with FDA Approval for TG Therapeutics Azer-Cel in Multiple Sclerosis Investigation By for CSIMarket.com Durham, N.C. Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene ed...

The realm of gene editing is witnessing transformative advancements, and at the forefront of this evolution is Precision BioSciences, Inc. (Nasdaq: DTIL). The recent announcement regarding the U.S. Food and Drug Adminis...

Precision BioSciences: Pioneering Advances in Gene Editing and Multiple Sclerosis TreatmentIn recent announcements, Precision BioSciences, Inc. (Nasdaq: DTIL), a pioneering gene editing company, has made significant str...

Precision BioSciences: Pioneering Gene Editing Advancements With Financial Growth and Expanding Expertise DURHAM, N.C. Precision BioSciences, Inc. (Nasdaq: DTIL), a vanguard in the field of gene editing, has recently an...

Precision BioSciences Expands its Presence and Advances Hepatitis Research with New Appointments and Clinical DataDURHAM, N.C. - Precision BioSciences, an advanced gene editing company utilizing its proprietary ARCUS pl...

Precision BioSciences Presents at UMDF Mitochondrial Medicine 2024, Advances PBGENE-PMM Program Towards IND and CTA Submission in 2025Durham, N.C. - June 26, 2024: Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced...

Precision BioSciences Bolsters Hepatitis Scientific Advisory Board with Mark Sulkowski and Jordan Feld as PBGENE-HBV Program AdvancesDURHAM, N.C. - Precision BioSciences, a leading gene editing company specializing in a...

Precision BioSciences, an advanced gene editing company utilizing its novel ARCUS platform, has recently made significant strides in the development of gene editing therapies. The company will be presenting preclinical...

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business UpdateDURHAM, N.C. - Precision BioSciences, Inc. (Nasdaq: DTIL), a pioneering gene editing company, announced its financial result...

In the dynamic world of genetic science, a significant breakthrough underpins the treatment of a rare inherited disorder, Ornithine Transcarbamylase (OTC) deficiency, as breakthrough innovator, Precision BioSciences, In...

The company s ground-breaking preclinical data from its pipeline candidate, PBGENE-HBV, for chronic hepatitis B (HBV) treatment will be the core focus of this forthcoming presentation. The exceptional data pointing towa...